Literature DB >> 22014151

In vivo optical imaging of membrane-type matrix metalloproteinase (MT-MMP) activity.

Lei Zhu1, Fan Zhang, Ying Ma, Gang Liu, Kwangmeyung Kim, Xuexun Fang, Seulki Lee, Xiaoyuan Chen.   

Abstract

Herein we demonstrate for the first time that a fluorogenic probe can be used as an in vivo imaging agent for visualizing activities of membrane-tethered, membrane-type matrix metalloproteinases (MT-MMPs). An MT-MMP fluorogenic probe that consisted of an MT1-MMP (MMP-14) substrate and near-infrared (NIR) dye-quencher pair exhibited rapid, efficient boosts in fluorescence upon cleavage by MT1-MMP in tumor-bearing mice. In particular, unlike similar fluorogenic probes designed to target extracellular, soluble-type MMPs (EC-MMPs)--which can be cleared from the bloodstream after activation--the fluorescence signals activated by MT1-MMP enable clear visualization of MT1-MMP-positive tumors in animal models for up to 24 h. The results indicate that a simple form of a fluorogenic probe that is less effective in EC-MMP imaging is an effective probe for imaging MT-MMP activities in vivo. These findings can be widely applied to designing probes and to applications targeting various membrane-anchored proteases in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22014151      PMCID: PMC3230704          DOI: 10.1021/mp2002297

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  33 in total

1.  In vivo molecular target assessment of matrix metalloproteinase inhibition.

Authors:  C Bremer; C H Tung; R Weissleder
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

2.  Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques.

Authors:  Yuji Kuge; Nozomi Takai; Yuki Ogawa; Takashi Temma; Yan Zhao; Kantaro Nishigori; Seigo Ishino; Junko Kamihashi; Yasushi Kiyono; Masashi Shiomi; Hideo Saji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

3.  In vivo evaluation of a new magnetic resonance imaging contrast agent (P947) to target matrix metalloproteinases in expanding experimental abdominal aortic aneurysms.

Authors:  Romain Bazeli; Michèle Coutard; Benjamin Daumas Duport; Eric Lancelot; Claire Corot; Jean-Pierre Laissy; Didier Letourneur; Jean-Baptiste Michel; Jean-Michel Serfaty
Journal:  Invest Radiol       Date:  2010-10       Impact factor: 6.016

Review 4.  Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion.

Authors:  Motoharu Seiki
Journal:  Cancer Lett       Date:  2003-05-08       Impact factor: 8.679

5.  High-affinity peptide against MT1-MMP for in vivo tumor imaging.

Authors:  Lei Zhu; Huiling Wang; Lin Wang; Ye Wang; Kun Jiang; Cheng Li; Qingjie Ma; Shi Gao; Liping Wang; Wei Li; Mingjun Cai; Hongda Wang; Gang Niu; Seulki Lee; Wei Yang; Xuexun Fang; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-02-02       Impact factor: 9.776

Review 6.  Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

Authors:  Roopali Roy; Jiang Yang; Marsha A Moses
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

7.  Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases.

Authors:  Emilia S Olson; Tao Jiang; Todd A Aguilera; Quyen T Nguyen; Lesley G Ellies; Miriam Scadeng; Roger Y Tsien
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

8.  Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination.

Authors:  Natalie M Moss; Maria V Barbolina; Yueying Liu; Limin Sun; Hidayatullah G Munshi; M Sharon Stack
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

9.  Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding.

Authors:  Georgina S Butler; Richard A Dean; Eric M Tam; Christopher M Overall
Journal:  Mol Cell Biol       Date:  2008-05-27       Impact factor: 4.272

Review 10.  Imaging matrix metalloproteinases in cancer.

Authors:  Randy L Scherer; J Oliver McIntyre; Lynn M Matrisian
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

View more
  14 in total

1.  Activatable near-infrared fluorescent probe for in vivo imaging of fibroblast activation protein-alpha.

Authors:  Jinbo Li; Kai Chen; Hongguang Liu; Kai Cheng; Meng Yang; Jiping Zhang; Jonathan D Cheng; Yan Zhang; Zhen Cheng
Journal:  Bioconjug Chem       Date:  2012-07-31       Impact factor: 4.774

2.  Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models.

Authors:  Benjamin B Kasten; Ke Jiang; Denzel Cole; Aditi Jani; Neha Udayakumar; G Yancey Gillespie; Guolan Lu; Tingting Dai; Eben L Rosenthal; James M Markert; Jianghong Rao; Jason M Warram
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-26       Impact factor: 9.236

Review 3.  Chemical biology for understanding matrix metalloproteinase function.

Authors:  Anna Knapinska; Gregg B Fields
Journal:  Chembiochem       Date:  2012-08-30       Impact factor: 3.164

4.  Noninvasive monitoring of pulmonary fibrosis by targeting matrix metalloproteinases (MMPs).

Authors:  Yan Cai; Lei Zhu; Fan Zhang; Gang Niu; Seulki Lee; Shioko Kimura; Xiaoyuan Chen
Journal:  Mol Pharm       Date:  2013-05-08       Impact factor: 4.939

5.  Targeting tumor hypoxia with 2-nitroimidazole-indocyanine green dye conjugates.

Authors:  Yan Xu; Saeid Zanganeh; Innus Mohammad; Andres Aguirre; Tianheng Wang; Yi Yang; Liisa Kuhn; Michael B Smith; Quing Zhu
Journal:  J Biomed Opt       Date:  2013-06       Impact factor: 3.170

Review 6.  Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.

Authors:  Orit Jacobson; Xiaoyuan Chen
Journal:  Pharmacol Rev       Date:  2013-09-24       Impact factor: 25.468

7.  Rational design of matrix metalloproteinase-13 activatable probes for enhanced specificity.

Authors:  Lei Zhu; Ying Ma; Dale O Kiesewetter; Ye Wang; Lixin Lang; Seulki Lee; Gang Niu; Xiaoyuan Chen
Journal:  ACS Chem Biol       Date:  2013-12-03       Impact factor: 5.100

8.  Development of a Radiolabeled Peptide-Based Probe Targeting MT1-MMP for Breast Cancer Detection.

Authors:  Kaiyin Min; Bin Ji; Min Zhao; Tiefeng Ji; Bin Chen; Xuedong Fang; Qingjie Ma
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

Review 9.  PET imaging of inflammation biomarkers.

Authors:  Chenxi Wu; Fang Li; Gang Niu; Xiaoyuan Chen
Journal:  Theranostics       Date:  2013-06-24       Impact factor: 11.556

10.  Monitoring and Inhibiting MT1-MMP during Cancer Initiation and Progression.

Authors:  Sonia Pahwa; Maciej J Stawikowski; Gregg B Fields
Journal:  Cancers (Basel)       Date:  2014-02-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.